“Secukinumab Reduces Endothelial Dysfunction in Subjects With Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S20, https://doi.org/10.25251/skin.2.supp.20.